TGFB1 and pancreatic neoplasm: Targeting FoxP3+ T-regs and IL35+ B-regs in combination with pharmacological inhibition of suppressive cytokines, such as TGFβ and IL6, rendered pancreatic tumors sensitive to anti-PD1 therapy [281, 284, 285].